MYC and prostate cancer

Cheryl M. Koh, Charles J. Bieberich, Chi V. Dang, William G Nelson, S Yegnasubramanian, Angelo Michael Demarzo

Research output: Contribution to journalArticle

Abstract

Prostate cancer, the majority of which is adenocarcinoma, is the most common epithelial cancer affecting a majority of elderly men in Western nations. Its manifestation, however, varies from clinically asymptomatic insidious neoplasms that progress slowly and do not threaten life to one that is highly aggressive with a propensity for metastatic spread and lethality if not treated in time. A number of somatic genetic and epigenetic alterations occur in prostate cancer cells. Some of these changes, such as loss of the tumor suppressors PTEN and p53, are linked to disease progression. Others, such as ETS gene fusions, appear to be linked more with early phases of the disease, such as invasion. Alterations in chromosome 8q24 in the region of MYC have also been linked to disease aggressiveness for many years. However, a number of recent studies in human tissues have indicated that MYC appears to be activated at the earliest phases of prostate cancer (e.g., in tumor-initiating cells) in prostatic intraepithelial neoplasia, a key precursor lesion to invasive prostatic adenocarcinoma. The initiation and early progression of prostate cancer can be recapitulated in genetically engineered mouse models, permitting a richer understanding of the cause and effects of loss of tumor suppressors and activation of MYC. The combination of studies using human tissues and mouse models paints an emerging molecular picture of prostate cancer development and early progression. This picture reveals that MYC contributes to disease initiation and progression by stimulating an embryonic stem cell-like signature characterized by an enrichment of genes involved in ribosome biogenesis and by repressing differentiation. These insights pave the way to potential novel therapeutic concepts based on MYC biology.

Original languageEnglish (US)
Pages (from-to)617-628
Number of pages12
JournalGenes and Cancer
Volume1
Issue number6
DOIs
StatePublished - 2010

Fingerprint

Prostatic Neoplasms
Disease Progression
Neoplasms
Adenocarcinoma
Prostatic Intraepithelial Neoplasia
Paint
Neoplastic Stem Cells
Gene Fusion
Embryonic Stem Cells
Ribosomes
Epigenomics
Chromosomes
Genes
Therapeutics

Keywords

  • Prostate cancer
  • Prostatic intraepithelial neoplasia
  • Tumor initiating cells

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

MYC and prostate cancer. / Koh, Cheryl M.; Bieberich, Charles J.; Dang, Chi V.; Nelson, William G; Yegnasubramanian, S; Demarzo, Angelo Michael.

In: Genes and Cancer, Vol. 1, No. 6, 2010, p. 617-628.

Research output: Contribution to journalArticle

Koh, Cheryl M. ; Bieberich, Charles J. ; Dang, Chi V. ; Nelson, William G ; Yegnasubramanian, S ; Demarzo, Angelo Michael. / MYC and prostate cancer. In: Genes and Cancer. 2010 ; Vol. 1, No. 6. pp. 617-628.
@article{d7ea65955225464f942ca388b9362f32,
title = "MYC and prostate cancer",
abstract = "Prostate cancer, the majority of which is adenocarcinoma, is the most common epithelial cancer affecting a majority of elderly men in Western nations. Its manifestation, however, varies from clinically asymptomatic insidious neoplasms that progress slowly and do not threaten life to one that is highly aggressive with a propensity for metastatic spread and lethality if not treated in time. A number of somatic genetic and epigenetic alterations occur in prostate cancer cells. Some of these changes, such as loss of the tumor suppressors PTEN and p53, are linked to disease progression. Others, such as ETS gene fusions, appear to be linked more with early phases of the disease, such as invasion. Alterations in chromosome 8q24 in the region of MYC have also been linked to disease aggressiveness for many years. However, a number of recent studies in human tissues have indicated that MYC appears to be activated at the earliest phases of prostate cancer (e.g., in tumor-initiating cells) in prostatic intraepithelial neoplasia, a key precursor lesion to invasive prostatic adenocarcinoma. The initiation and early progression of prostate cancer can be recapitulated in genetically engineered mouse models, permitting a richer understanding of the cause and effects of loss of tumor suppressors and activation of MYC. The combination of studies using human tissues and mouse models paints an emerging molecular picture of prostate cancer development and early progression. This picture reveals that MYC contributes to disease initiation and progression by stimulating an embryonic stem cell-like signature characterized by an enrichment of genes involved in ribosome biogenesis and by repressing differentiation. These insights pave the way to potential novel therapeutic concepts based on MYC biology.",
keywords = "Prostate cancer, Prostatic intraepithelial neoplasia, Tumor initiating cells",
author = "Koh, {Cheryl M.} and Bieberich, {Charles J.} and Dang, {Chi V.} and Nelson, {William G} and S Yegnasubramanian and Demarzo, {Angelo Michael}",
year = "2010",
doi = "10.1177/1947601910379132",
language = "English (US)",
volume = "1",
pages = "617--628",
journal = "Genes and Cancer",
issn = "1947-6019",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - MYC and prostate cancer

AU - Koh, Cheryl M.

AU - Bieberich, Charles J.

AU - Dang, Chi V.

AU - Nelson, William G

AU - Yegnasubramanian, S

AU - Demarzo, Angelo Michael

PY - 2010

Y1 - 2010

N2 - Prostate cancer, the majority of which is adenocarcinoma, is the most common epithelial cancer affecting a majority of elderly men in Western nations. Its manifestation, however, varies from clinically asymptomatic insidious neoplasms that progress slowly and do not threaten life to one that is highly aggressive with a propensity for metastatic spread and lethality if not treated in time. A number of somatic genetic and epigenetic alterations occur in prostate cancer cells. Some of these changes, such as loss of the tumor suppressors PTEN and p53, are linked to disease progression. Others, such as ETS gene fusions, appear to be linked more with early phases of the disease, such as invasion. Alterations in chromosome 8q24 in the region of MYC have also been linked to disease aggressiveness for many years. However, a number of recent studies in human tissues have indicated that MYC appears to be activated at the earliest phases of prostate cancer (e.g., in tumor-initiating cells) in prostatic intraepithelial neoplasia, a key precursor lesion to invasive prostatic adenocarcinoma. The initiation and early progression of prostate cancer can be recapitulated in genetically engineered mouse models, permitting a richer understanding of the cause and effects of loss of tumor suppressors and activation of MYC. The combination of studies using human tissues and mouse models paints an emerging molecular picture of prostate cancer development and early progression. This picture reveals that MYC contributes to disease initiation and progression by stimulating an embryonic stem cell-like signature characterized by an enrichment of genes involved in ribosome biogenesis and by repressing differentiation. These insights pave the way to potential novel therapeutic concepts based on MYC biology.

AB - Prostate cancer, the majority of which is adenocarcinoma, is the most common epithelial cancer affecting a majority of elderly men in Western nations. Its manifestation, however, varies from clinically asymptomatic insidious neoplasms that progress slowly and do not threaten life to one that is highly aggressive with a propensity for metastatic spread and lethality if not treated in time. A number of somatic genetic and epigenetic alterations occur in prostate cancer cells. Some of these changes, such as loss of the tumor suppressors PTEN and p53, are linked to disease progression. Others, such as ETS gene fusions, appear to be linked more with early phases of the disease, such as invasion. Alterations in chromosome 8q24 in the region of MYC have also been linked to disease aggressiveness for many years. However, a number of recent studies in human tissues have indicated that MYC appears to be activated at the earliest phases of prostate cancer (e.g., in tumor-initiating cells) in prostatic intraepithelial neoplasia, a key precursor lesion to invasive prostatic adenocarcinoma. The initiation and early progression of prostate cancer can be recapitulated in genetically engineered mouse models, permitting a richer understanding of the cause and effects of loss of tumor suppressors and activation of MYC. The combination of studies using human tissues and mouse models paints an emerging molecular picture of prostate cancer development and early progression. This picture reveals that MYC contributes to disease initiation and progression by stimulating an embryonic stem cell-like signature characterized by an enrichment of genes involved in ribosome biogenesis and by repressing differentiation. These insights pave the way to potential novel therapeutic concepts based on MYC biology.

KW - Prostate cancer

KW - Prostatic intraepithelial neoplasia

KW - Tumor initiating cells

UR - http://www.scopus.com/inward/record.url?scp=78650104069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650104069&partnerID=8YFLogxK

U2 - 10.1177/1947601910379132

DO - 10.1177/1947601910379132

M3 - Article

C2 - 21779461

AN - SCOPUS:78650104069

VL - 1

SP - 617

EP - 628

JO - Genes and Cancer

JF - Genes and Cancer

SN - 1947-6019

IS - 6

ER -